8-K: Damora Therapeutics Appoints New CEO, Reshapes Board

Damora Therapeutics announced the appointment of Jennifer Jarrett as President and CEO, alongside significant changes to its Board of Directors.

Summary

• Jennifer Jarrett has been appointed President and Chief Executive Officer of Damora Therapeutics, Inc., effective March 30, 2026.
• Ms. Jarrett will also join the company's Board of Directors as a Class II director.
• Sherwin Sattarzadeh will continue in his role as Chief Operating Officer, with Ms. Jarrett succeeding him as Principal Executive Officer.
• Three directors, Amit Munshi, Carl Goldfischer, and Jayson Dallas, resigned from the Board effective March 23, 2026; their resignations were not due to disagreements with the company.
• Michael Landsittel and Cameron Turtle, D.Phil., were appointed to the Board as Class III directors, effective March 23, 2026.
• Mr. Landsittel will chair the audit committee and serve on the nominating and corporate governance committee, while Dr. Turtle will join the audit committee.
• The Board's size has been reduced from seven to six members, and Peter Harwin has been named Chairman of the Board, both effective March 23, 2026.
• Jennifer Jarrett's compensation includes an annual base salary of $695,000, a target annual bonus of 55% of her base salary, 500,000 restricted stock units, and options to purchase 1,500,000 shares of common stock.
• Garrett Winslow, General Counsel and Corporate Secretary, entered into a new offer letter with an annual base salary of $440,000, a target annual bonus of 40% of his base salary, and options to purchase 250,000 shares of common stock.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, reflecting a strategic strengthening of leadership and governance, which is crucial for a biotechnology company advancing its pipeline. The extensive experience of the new CEO and board members is a significant asset.

Positives

• Appointment of Jennifer Jarrett as CEO brings nearly three decades of executive leadership experience in biotech, tech, and finance, including prior roles as COO of Arcus Biosciences and CFO of Medivation.
• The addition of Michael Landsittel and Cameron Turtle to the Board brings extensive experience in strategic finance, corporate development, and building biopharma organizations from development to commercialization.
• The new leadership team and board members are expected to accelerate efforts to bring innovative medicines to patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs).
• The company has a stated portfolio of potential best-in-class therapies and a strong balance sheet, positioning it well for rapid development of its lead program, DMR-001, and other pipeline assets.

Negatives

• The resignation of three directors, while stated not to be due to disagreements, represents a significant turnover in board composition.

Risks

• Forward-looking statements involve risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied.
• There is no assurance that future developments affecting the company will be those anticipated.
• Risks and uncertainties are described under 'Risk Factors' in the company's most recent SEC filings.

Future Outlook

The company aims to fundamentally redefine care for patients with blood disorders, specifically advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms. The lead program, DMR-001, is expected to be rapidly developed, with multiple programs on track to enter clinical development in 2026. The goal is to bring forward optimized therapies with broad mutation coverage and exceptional convenience to improve patient outcomes.

Management Comments

• "We are excited to welcome Jen to Damora as we accelerate our efforts to bring innovative medicines to patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm (MPNs). With a track record of success in oncology drug development and building and leading high-growth companies, Jen brings a unique set of strategic and operational experience that will be invaluable as we unlock Damora's potential." Peter Harwin, Chairman of the Board of Directors.
• "I am thrilled to join Damora, and I look forward to working alongside the company's talented and purpose-driven employees to realize our mission of redefining care for people with blood disorders. With a portfolio of potential best-in-class therapies, a strong balance sheet, and experienced board and executive leadership, Damora is exceptionally well positioned to rapidly develop our lead program, DMR-001, while also strategically advancing additional pipeline assets to treat the full spectrum of patients with mutCALR-driven MPNs." Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics.
• "Cameron and Mike bring to Damora incredible experience building and leading successful companies from development to commercialization across global markets, with a deep understanding of the biotech landscape and capital markets. We welcome their complementary expertise and perspective to our board." Peter Harwin.
• "The Board of Directors also extends our gratitude to departing directors Dr. Carl Goldfischer, Dr. Jayson Dallas and Amit Munshi for their vision and leadership, which enabled the recent Damora-Galecto transaction and our strategy to deliver value to patients and shareholders." Peter Harwin.

Industry Context

StockSavvy.ai notes that the appointment of a seasoned biotech executive like Jennifer Jarrett, with a strong background in oncology drug development, finance, and corporate strategy, signals Damora Therapeutics' intent to aggressively advance its pipeline in blood disorders. The simultaneous addition of experienced board members like Michael Landsittel (former CFO of Blueprint Medicines) and Cameron Turtle (CEO of Spyre Therapeutics) further strengthens the company's strategic and financial oversight, aligning with a trend in the biotech industry to bring in proven leaders for late-stage development and commercialization efforts. This move positions Damora to compete more effectively in the specialized field of myeloproliferative neoplasms.

Comparison to Industry Standards

• Jennifer Jarrett's background, including her role as COO of Arcus Biosciences (a late clinical-stage biopharmaceutical company) and CFO of Medivation (a commercial oncology company acquired by Pfizer), aligns with the industry standard of appointing CEOs with a blend of operational, financial, and drug development expertise for companies transitioning or scaling their clinical programs.
• Michael Landsittel's experience as CFO of Blueprint Medicines, where he led efforts to raise approximately $4 billion in capital and transition the company to a commercial immunology focus, demonstrates a track record comparable to financial leaders at successful growth-stage biopharmaceutical companies.
• Cameron Turtle's leadership at Spyre Therapeutics and prior roles at BridgeBio Pharma and Eidos Therapeutics, where he advanced investigational medicines, reflects the industry's demand for directors with deep scientific and business development acumen in clinical-stage biotechnology.
• The compensation packages for the new CEO and General Counsel, including substantial equity awards, are competitive within the biotech industry for attracting and retaining high-caliber executive talent, particularly for companies with promising pipelines and significant growth ambitions.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The appointment of an experienced CEO and new directors with strong industry backgrounds could instill confidence, potentially leading to positive share price movement due to perceived improved leadership and strategic execution.
• **Employees**: The new CEO's vision for redefining care and advancing the pipeline could provide a clear strategic direction and motivation. The continued employment offer for the General Counsel indicates stability in key legal functions.
• **Customers (Patients)**: The stated goal of accelerating innovative medicines for blood disorders, including DMR-001, suggests a commitment to addressing significant medical needs and improving patient outcomes.
• **Creditors**: A strengthened leadership team and a stated 'strong balance sheet' could enhance the company's perceived financial stability and ability to meet its obligations.
• **Suppliers**: A clear strategic direction and focus on pipeline development could lead to stable or increased demand for services and materials from suppliers supporting R&D and clinical trials.

Next Steps

• Jennifer Jarrett's employment as President and CEO will commence on March 30, 2026.
• The company will proceed with the rapid development of its lead program, DMR-001.
• Additional pipeline assets are planned for strategic advancement to treat the full spectrum of patients with mutCALR-driven MPNs.
• Multiple programs are on track to enter clinical development in 2026.
• Ms. Jarrett, Mr. Landsittel, and Dr. Turtle will enter into standard indemnification agreements with the company.

Key Dates

Recommendation

The appointment of Jennifer Jarrett as CEO, a highly experienced leader in biotech, finance, and oncology drug development, coupled with the addition of two seasoned industry veterans to the Board, significantly strengthens Damora Therapeutics' leadership and strategic capabilities. This move signals a clear intent to accelerate the development of its pipeline, particularly DMR-001 for blood disorders, which has 'best-in-class potential.' The restructuring of the board, while involving resignations, appears to be a strategic move to bring in complementary expertise for growth and commercialization. These changes are highly positive for the company's future prospects and warrant a 'buy' recommendation for investors looking for long-term growth in the biotechnology sector.

Keywords

Biotechnology, CEO Appointment, Board of Directors, Corporate Governance, Executive Compensation, Biopharma, Blood Disorders, Myeloproliferative Neoplasms, DMR-001, Nasdaq